As the chief scientific officer of the Leukemia & Lymphoma Society for the past eleven years, it has been a privilege to lead a group of scientists that has doled out more than $600 million for cutting-edge hematologic oncology research. These dollars went to more than 1,000 research projects through initiatives like our biomedical research grant programs and LLS’s venture philanthropy, the Therapy Acceleration Program (TAP).
Oncological clinical trials pave the way for better patient outcomes and accelerate critical cancer treatments. Their legacy structure, however, often stands in their own way.
ASCO and Conquer Cancer, the ASCO Foundation, will recognize researchers, patient advocates, philanthropists, teachers, and global oncology leaders who have reshaped cancer care around the world with the society’s highest honors at the 2025 ASCO Annual Meeting.
Walter M. Stadler was appointed as the chief clinical officer at City of Hope Cancer Center Chicago.
Investigators at the UCLA Health Jonsson Comprehensive Cancer Center have been awarded a $1.72 million grant from NIH to support the Neuro-Oncology Translational Research Training Program, an initiative designed to train the next generation of brain tumor scientists and physician-scientists.
Tampa General Hospital has been awarded Quality Oncology Practice Initiative Certification based on the approval of the ASCO. This voluntary certification specifically recognizes the TGH Cancer Institute for meeting the strict standards required by the society’s QOPI program.
The Community Oncology Alliance released the COA Prescription for Health Care Reform, a blueprint that diagnoses the fundamental challenges facing the U.S. healthcare system, outlines the consequences for patients across America, and presents “actionable solutions .”
The Wistar Institute’s Hubert J.P. Schoemaker Education and Training Center is expanding its apprenticeship programs and bolstering job opportunities in the life science sector based on a recent $600,000 PASmart Grant from the Pennsylvania Department of Labor & Industry.
A phase III clinical trial co-led by a researcher at UT Southwestern Harold C. Simmons Comprehensive Cancer Center showcases the promise of administering immunotherapy along with chemotherapy before surgery in patients with breast cancer at high risk of spreading.
Dana-Farber Cancer Institute researchers report that all nine patients in a clinical trial being treated for stage 3 or 4 clear cell renal cell carcinoma generated a successful anti-cancer immune response after initiation of a personalized cancer vaccine.
